# Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

> **NCT01634763** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

## Interventions

- **DRUG:** LDK378

## Key facts

- **NCT ID:** NCT01634763
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634763, "Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01634763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*